Psoriasis Club
  • Forum
  • Home
  • Portal
  • Member List
  • Psoriasis Score
  • PQOLS
  • What is psoriasis
  • Search
  • Help
Hello Guest, Welcome To The Psoriasis Club Forum. We are a self funded friendly group of people who understand.
Never be alone with psoriasis, come and join us. (Members have more privileges)
wave
Login Register
Login
Username:
Password:
Lost Password?
 
Psoriasis Club › HealthHealth Boards › Psoriasis In The News v
1 2 3 4 5 … 49 Next »

Bimzelx gets FDA acceptance for resubmission

Threaded Mode
Bimzelx gets FDA acceptance for resubmission
Fred Offline
I Wanted To Change the World But Got Up Far Too Late.
Moderator
Posts: 57,003
Threads: 3,553
Joined: Aug 2011
Gender: Male
Location: France
Psoriasis Score: 1
Psoriatic Arthritis Score: 1
PQOLS: 2
Treatment: Bimzelx / Coconut Oil
#1
News  Fri-23-12-2022, 14:01 PM
Following on from this thread Bimzelx FDA cannot approve the application in its current form the U.S. Food and Drug Administration (FDA) has accepted for review the Biologics License Application (BLA) resubmission for Bimzelx (bimekizumab) for the treatment of adults with moderate to severe plaque psoriasis.

Quote:
UCB, a global biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the Biologics License Application (BLA) resubmission for bimekizumab for the treatment of adults with moderate to severe plaque psoriasis. The FDA designated the resubmission as ‘Class 2’ with a six-month review period. The FDA action is expected in the second quarter of 2023. 

“The FDA acceptance of our resubmitted application for bimekizumab is positive news that moves us one step closer to providing the first dual IL-17A and IL-17F inhibitor to address the unmet needs of people with moderate to severe plaque psoriasis in the U.S. We will continue to work with the FDA through the review process with the goal of bringing bimekizumab to the dermatology community in the U.S. as soon as possible,” said Emmanuel Caeymaex, Executive Vice President, Immunology Solutions and Head of U.S., UCB.

In November 2022, UCB announced resubmission of the BLA for bimekizumab, for the treatment of adults with moderate to severe plaque psoriasis, following receipt of a complete response letter in May 2022. 

Source: ucb.com

Bimzelx (bimekizumab)
Quote
« Next Oldest | Next Newest »


Possibly Related Threads…
Thread Author Replies Views Last Post
News Bimzelx FDA cannot approve the application in its current form Fred 2 1,067 Sun-15-05-2022, 07:53 AM
Last Post: KatT
News Bimzelx psoriatic arthritis phase 3 results Fred 4 1,962 Sat-22-01-2022, 10:05 AM
Last Post: Caroline
News Bimzelx for psoriasis two year data Fred 4 2,015 Thu-30-09-2021, 19:53 PM
Last Post: Fred
News Bimzelx gets positive opinion from (CHMP) for psoriasis Fred 0 761 Mon-28-06-2021, 12:25 PM
Last Post: Fred
News Xeljanz gets FDA acceptance for review Fred 3 3,588 Thu-05-02-2015, 02:13 AM
Last Post: jiml



Users browsing this thread: 1 Guest(s)
    Contact us | Login | Register | Home | Cookies/GDPR | RSS Syndication | Portal | Types Of Psoriasis | Psoriasis Score | Members Only Boards
    Copyright © 2010 - 2023 Psoriasis Club All Rights Reserved | Founded May 2010 | Psoriasis Club Is Self Funded Without Sponsors Or Donations | Software by MyBB | Social
Linear Mode
Threaded Mode